Altimmune, Inc. develops pemvidutide, a late clinical-stage dual-action therapy targeting glucagon and GLP-1 receptors for serious liver diseases. Company news centers on pemvidutide development in metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), including clinical trial updates and FDA designations such as Fast Track and Breakthrough Therapy Designation where granted.
Altimmune updates also cover financial results, business updates, investor conference participation and capital actions used to fund development activity. Recurring financing news includes public offerings, registered direct offerings, common stock, pre-funded warrants and common stock warrants.
Altimmune (ALT) reported a third-quarter 2026 net loss of $31.608 million while advancing clinical trials of pemvidutide for liver diseases. The loss widened from $19.014 million a year earlier, although loss per share narrowed to $0.15 from $0.21. Cash, cash equivalents and investments totaled $480 million at September 30, 2026.
The company said its global PERFORMA Phase 3 trial in metabolic dysfunction-associated steatohepatitis, or MASH, is progressing as planned, with 52-week topline results anticipated in 2029. Pemvidutide received FDA Breakthrough Therapy Designation for MASH and Fast Track designation for alcohol use disorder. An FDA meeting to discuss a Phase 3 alcohol use disorder program is scheduled for December 2026. Enrollment is complete in RESTORE, the Phase 2 alcohol-associated liver disease trial, with topline results expected in the second half of 2027.
Altimmune (Nasdaq: ALT) announced publication of its IMPACT Phase 2b pemvidutide trial results in patients with metabolic dysfunction-associated steatohepatitis (MASH). The Lancet Gastroenterology & Hepatology paper reports 48-week secondary endpoints of MASH resolution and fibrosis improvement, or reduced liver scarring. Treatment produced significant reductions versus placebo in non-invasive measures of liver fat, inflammation and fibrosis, alongside significant weight loss.
Weight loss with 1.8 mg appeared to continue through week 48. Blood sugar control was maintained, with no significant heart-rate changes or imbalance in cardiac adverse events versus placebo. Approximately 1% of pemvidutide patients discontinued because of adverse events. Most adverse events were mild to moderate; gastrointestinal events predominantly occurred within the first eight weeks. The PERFORMA Phase 3 trial is ongoing.
Altimmune (ALT) presented Phase 2 RECLAIM results showing pemvidutide reduced heavy drinking days in adults with moderate-to-severe alcohol use disorder. At Week 24, the primary endpoint was met: heavy drinking days per week fell by 4.20 days versus 2.75 with placebo (p=0.0014). Zero heavy drinking days were achieved by 42.2% versus 17.4%, while abstinent days increased to 38.9% versus 20.5%. Weight and liver-health measures also improved.
Adverse events were primarily mild-to-moderate, but gastrointestinal events were more frequent with pemvidutide. Treatment discontinuation was 20% versus 22% with placebo. Altimmune has an FDA End-of-Phase 2 meeting scheduled in December on its Phase 3 program design for alcohol use disorder. Separate 48-week IMPACT Phase 2b analyses in metabolic dysfunction-associated steatohepatitis showed improvements in liver measures versus placebo, with no severe gastrointestinal treatment-emergent adverse events.
Altimmune (ALT) will present RECLAIM Phase 2 results for pemvidutide in alcohol use disorder at The Liver Meeting on November 9, 2026.
The late-breaking oral presentation covers adults with moderate-to-severe alcohol use disorder. The randomized, double-blind, placebo-controlled trial compared once-weekly pemvidutide 2.4 mg with placebo over 24 weeks. Topline results announced in July 2026 showed a statistically significant reduction in heavy drinking days per week versus placebo, meeting the primary endpoint. The trial also met key secondary endpoints, including reduced World Health Organization Risk Drinking Levels and zero heavy drinking days. Altimmune described tolerability as generally favorable.
An End-of-Phase 2 FDA meeting is scheduled for December to discuss the Phase 3 registrational program for pemvidutide in alcohol use disorder.
Altimmune (Nasdaq: ALT) will report its third quarter 2026 financial results and provide a business update on November 12, 2026. Management will host a conference call at 8:30 a.m. ET that day. A live webcast will be available on the company’s Investor Relations website, with a replay available shortly afterward for up to three months.
Altimmune (Nasdaq: ALT) appointed Peter Greenleaf and Alex Howarth to its board of directors, effective November 2, 2026. As part of the planned transition, John M. Gill, Mitchel Sayare and Klaus O. Schafer will retire and not seek reelection when their current one-year terms end at the 2027 Annual Meeting.
The company links the board changes to its transition toward late-stage development of pemvidutide, an investigational treatment for serious liver diseases. Its Phase 3 MASH trial is funded and ongoing. Greenleaf most recently served as CEO of Aurinia Pharmaceuticals, where he guided its transition from development to commercialization. Howarth most recently served as CFO of Madrigal Pharmaceuticals, helping its transition into a commercial organization that launched the first approved treatment for MASH.
Altimmune (Nasdaq: ALT) will present new pemvidutide clinical and preclinical data at AASLD’s The Liver Meeting on November 5–9, 2026.
In 48-week analyses of the IMPACT Phase 2b study in metabolic dysfunction-associated steatohepatitis (MASH), pemvidutide reduced liver stiffness and ELF score, two non-invasive markers of scarring, alongside liver fat and alanine aminotransferase compared with placebo. Gastrointestinal adverse events were mild to moderate, with none severe. Discontinuations due to adverse events were lower than with placebo, and more pemvidutide-treated patients completed treatment despite no dose titration. Preclinical results showed reduced mean alcohol intake in a hamster model. The company’s PERFORMA Phase 3 MASH trial is actively enrolling.
Altimmune (ALT) will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.
The company, which is developing pemvidutide for serious liver diseases, will provide live access via a webcast in the Events section of its website.
Altimmune (ALT) will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, at 9:30 a.m. ET.
The late clinical-stage biopharmaceutical company is developing pemvidutide for serious liver diseases, and will provide webcast access to the session via the Events section of its website.
Altimmune (Nasdaq: ALT) reported second quarter 2026 results and a business update, highlighting advancement of its lead candidate pemvidutide in serious liver diseases. The company ended June 30, 2026 with $519 million in cash, cash equivalents and investments, supported by a completed $225 million public offering in April.
Altimmune initiated the global PERFORMA Phase 3 MASH trial, after pemvidutide received FDA Breakthrough Therapy and Fast Track designations for MASH. In AUD, the RECLAIM Phase 2 trial met its primary endpoint with a statistically significant reduction in heavy drinking days and achieved key FDA‑recognized secondary endpoints, with a generally favorable safety profile. In ALD, the company fully enrolled the RESTORE Phase 2 trial and amended the protocol to more fully assess liver benefits, with topline data expected in the second half of 2027.
For Q2 2026, Altimmune recorded R&D expenses of $18.7 million, G&A expenses of $7.6 million, and a net loss of $22.8 million, or $0.12 per share, compared with a $22.1 million net loss, or $0.27 per share, in Q2 2025.